Objective: To determine whether susceptibility map-weighted imaging (SMWI) was superior to conventional susceptibility-weighted imaging (SWI) in the diagnosis of Parkinson's disease (PD) and in its correlation with 123I-2bcarbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane single photon emission computerized tomography (123I-FP-CIT SPECT). Methods: Between May 2017 and February 2018, 125 consecutive patients diagnosed with idiopathic PD, vascular pseudoparkinsonism, essential tremor, or drug-induced parkinsonism and who underwent 123I-FP-CIT SPECT imaging and 3 T SWI on the same day or within 3 months were included in this retrospective study. In all patients, SMWI images were generated from SWI images. On both MRIs, two neuroradiologists independently evaluated the status of nigral hyperintensity on each side of substantia nigra. Inter-observer agreements for the nigral hyperintensity were tested. Using consensus reading, concordance between SWI, SMWI, and 123I-FP-CIT SPECT were evaluated, and the diagnostic performance between SWI and SMWI for PD was compared. Results: Inter-observer agreement for the nigral hyperintensity was higher for SMWI (right, κ = 0.919; left, κ = 0.984) than for SWI (right, κ = 0.918; left, κ = 0.902). SMWI (right 67.2 %, left 68.0 %) showed a higher concordance rate with the results of 123I-FP-CIT SPECT than SWI (right 60.0 %, left 59.2 %). SMWI (area under curve [AUC], 0.791) provided significantly higher diagnostic performance for PD than SWI (AUC, 0.720; P = 0.0005). Conclusion: SMWI may be a superior assessment tool for nigral hyperintensity than SWI and may be an improved diagnostic imaging modality for patients with suspected PD.
- Nigral hyperintensity
- Parkinson's disease
- Susceptibility map-weighted imaging
- Susceptibility-weighted imaging